SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced a poster presentation at the EHA 2026 Congress…

Evaxion · PRESS-RELEASE filed May 12, 2026 at 09:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 12, 2026 at 09:30 ET

Evaxion announced a poster presentation at the EHA 2026 Congress detailing preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine. The data supports progression toward clinical testing, with a clinical trial application planned for H2 2026. This is a positive pipeline update but remains early-stage and non-revenue generating.

  • EVX-04 is an off-the-shelf therapeutic AML vaccine targeting endogenous retrovirus (ERV) tumor antigens.
  • Preclinical data will be presented at EHA 2026 Congress on June 13, 2026.
  • Evaxion plans to submit a clinical trial application in the second half of 2026.
  • EVX-04 prevented tumor growth in preclinical tumor models.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access